Brief: Recursion's Tupelo Trial Phase 1B/2 Results Show Polyp Burden Reductions In FAP At 25 Weeks

Recursion Pharmaceuticals

08/12/2025 12:30

Dec 8 (Reuters) - Recursion Pharmaceuticals Inc RXRX.O:

RECURSION: REC-4881 TUPELO TRIAL PHASE 1B/2 RESULTS SHOW RAPID & DURABLE REDUCTIONS IN POLYP BURDEN IN FAMILIAL ADENOMATOUS POLYPOSIS AT 25 WEEKS

RECURSION: 82% OF EVALUABLE PATIENTS OF REC-4881 TUPELO TRIAL MAINTAINED REDUCTIONS AT WEEK 25, WITH 53% MEDIAN DECREASE FROM BASELINE

RECURSION: REC-4881 HAS SAFETY PROFILE CONSISTENT WITH MEK1/2 INHIBITION

RECURSION: TO ENGAGE FDA IN 1H26 TO DEFINE POTENTIAL REGISTRATION PATHWAY FOR REC-4881

RECURSION: TO EXPAND POPULATION FROM ≥55 TO ≥18 YEARS OLD & FURTHER OPTIMIZE DOSING SCHEDULE FOR REC-4881

Further company coverage: RXRX.O

 ((Reuters.Briefs@thomsonreuters.com;))